What CoMind does

CoMind Technologies Limited is a London-based neurotechnology company developing non-invasive optical sensors for continuous monitoring of cerebral blood flow, intracranial pressure, and cerebral autoregulation. Its technology is built on a proprietary time-of-flight resolved interferometric sensing platform operating at 1064nm, derived from LiDAR-class photonics and adapted into a clinical-grade wearable intended to replace invasive intracranial bolts currently used in neurocritical care. The lead commercial product, the CoMind One, is planned for launch in 2027; the CoMind R1 serves as a research prototype supporting early clinical and academic engagement.

CoMind is pre-revenue and pre-FDA, with US clinical trials underway to support regulatory clearance. The company's go-to-market targets hospital ICUs, cardiac and vascular surgery units, and traumatic brain injury (TBI) settings where invasive neuromonitoring is the standard of care. To date, CoMind has raised approximately $102.5M across multiple rounds, including a $27M round in 2023 and a $60M Series A in October 2025 led by Plural. A manufacturing partnership with Benchmark supports production scale-up, and peer-reviewed validation has appeared in Neurophotonics (March 2026). The company is led by Chairman Frank Fischer (appointed March 2025) and operates with 51–100 employees, with the team weighted toward R&D, clinical, and regulatory functions rather than a deployed commercial salesforce.

The business model is a regulated medical-device sale into hospital systems, with revenue per device and recurring disposable or service economics typical of critical-care monitoring platforms, though no pricing, ASP, or contract structure has been disclosed. Strategic intent, as evidenced by the Series A use of funds, the US clinical program, and the Benchmark manufacturing partnership, is to clear FDA, launch the CoMind One in 2027, and establish CoMind as the first non-invasive clinical-grade alternative to invasive cerebral monitoring.

Name

CoMind

Legal name

CoMind Technologies Limited

Website

https://comind.io

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

CoMind Technologies Limited is a London-based neurotechnology company building non-invasive optical sensors that monitor cerebral blood flow, intracranial pressure, and autoregulation, targeting hospital neurocritical care, cardiac/vascular surgery, and TBI markets ahead of a planned 2027 launch.

Ownership category

akta.pro rank

Product category

Neuromonitoring Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841), Industrial Instruments For Measurement, Display, And Control (3823)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industry

Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)

Keywords

• Non-invasive neuromonitoring
• Brain monitoring devices
• Cerebral blood flow monitoring
• Intracranial pressure monitoring
• Optical sensing technology

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: CoMind One is a medical device that will be sold to healthcare providers (hospitals, ICUs). The company is preparing for commercial deployment and manufacturing scale-up.

Go-to-market motion2 records

Marketing channels4 records

Core offering

CoMind develops a non-invasive brain monitoring system (CoMind One) that uses time-of-flight resolved interferometric optical sensing with safe 1064nm infrared laser light to measure cerebral blood flow, intracranial pressure, and cerebral autoregulation. The device uses a small adhesive sensor placed on the patient's forehead, eliminating the need for invasive intracranial bolts that carry complication rates of up to 15 percent. The system delivers continuous, multi-parameter neurophysiological monitoring at the bedside for critical care, cardiac and vascular surgery, and traumatic brain injury management.

Product overview

CoMind is developing a non-invasive brain monitoring system centered around CoMind One, their primary clinical product designed for bedside monitoring of cerebral blood flow, intracranial pressure, and autoregulation using advanced optical sensing technology. The technology uses safe levels of laser light transmitted through head tissues with interferometric detection to provide depth-resolved sensitivity to blood flow dynamics. CoMind R1 serves as their research prototype that demonstrated the scientific foundation and technical performance required for clinical translation. The company aims to make brain tracking as simple and accessible as a pulse check, replacing the need for invasive intracranial procedures.

Differentiator

Problem solved

Functional benefit

Products and services

• CoMind One A non-invasive brain monitoring system designed for healthcare providers, providing real-time insight into cerebral perfusion, autoregulation, and intracranial pressure using advanced infrared light technology. Built around a simple adhesive forehead sensor, it delivers continuous brain physiology signals to clinicians across critical care settings including cardiac and vascular surgery, intensive care, and traumatic brain injury management.
• CoMind R1 A time-resolved interferometric optical neuromonitoring research prototype integrating a high-power linearly-swept 1064 nm laser with multimode fibre collection, parallelised detection, and real-time signal processing. Achieves an instrument response function width of 120 picoseconds with no significant drift over 24 hours of continuous operation, and has been used in studies of 25 healthy adults producing high-quality pulsatile cerebral blood flow waveforms.

Quantifiable outcome

• Traditional intracranial bolts lead to complications in up to 15 percent of cases
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• BenchmarkcoreStrategic or Co-development Partner · 24 October 2025CoMind has partnered with Benchmark as its development and manufacturing partner to create a non-invasive brain monitoring device. Benchmark provides manufacturing expertise to support the product development and eventual commercialization.
• Clinical Advisory BoardcoreOthers

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Medtronic's INVOS (In-Vivo Optical Spectroscopy) cerebral oximeter is a market-leading NIRS device used during cardiac surgery and in the ICU. As a diversified medical device incumbent with deep relationships across US hospital systems, it represents the entrenched incumbent CoMind must displace.
• Nihon Kohden: Nihon Kohden is a global leader in patient monitoring and neurological diagnostics (EEG, cerebral oximetry, neuromonitoring). As a diversified incumbent with strong hospital relationships in both US and Europe, it represents the integrated monitoring platform CoMind must integrate with or compete against.
• Natus Medical: Natus provides a broad portfolio of neurodiagnostic and neurocritical care devices including EEG, ICP monitors, and cerebral oximetry modules. As an established incumbent across multiple neurology/neurocritical care modalities, it competes for the same hospital budget.
• Edwards Lifesciences: Edwards' FORE-SIGHT cerebral oximeter is another FDA-cleared NIRS cerebral oxygenation monitor used in cardiac surgery and critical care. As part of Edwards' broader hemodynamic monitoring portfolio, it benefits from cross-selling into the same OR and ICU channels CoMind targets.

Direct peers

• Masimo: Masimo's O3 Regional Oximetry is an FDA-cleared NIRS-based cerebral oximeter used in ICU and perioperative settings. It is the closest direct competitor to CoMind One, addressing the same clinical need (non-invasive cerebral oxygenation) with an established hospital installed base.
• Ornim Medical: Ornim's CerOx device uses ultrasound-tagged NIRS (UT-NIRS) to non-invasively measure cerebral blood flow and oxygenation. As a startup focused exclusively on cerebral oximetry with novel optical approaches, it parallels CoMind's strategy of bringing next-generation physics to non-invasive brain monitoring.
• Nonin Medical: Nonin Medical manufactures NIRS-based cerebral oximeters (Equanox) for use in operating rooms and ICUs. It is a focused competitor in non-invasive cerebral monitoring, similar in product positioning to CoMind but lacking CoMind's depth-resolved ToF architecture.
• Moberg ICU Solutions: Moberg provides multimodal brain monitoring solutions for the ICU, including EEG and cerebral oximetry data aggregation. It competes with CoMind in the same ICU brain-monitoring niche and addresses similar clinical pain points around integrated bedside brain data.
• NovaSignal: NovaSignal develops the NovaGuide 2, an ultrasound-based system for non-invasive, real-time cerebral blood flow assessment. It competes with CoMind in the same clinical use case (non-invasive cerebral hemodynamics) using a different underlying physics modality.

Emerging players

• Hyperfine: Hyperfine developed the Swoop portable MRI for point-of-care brain imaging, addressing the same unmet need (better, more accessible brain assessment) in critical care. It is a comparable emerging player in novel bedside neurotechnology, though using a different modality (MRI vs. optics).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/comind_

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoMind